Wandong Medical updates on share buyback and cash management

Beijing Wandong Medical Technology is proceeding with its share repurchase program, initiated on August 22, 2025, with a planned duration until August 21, 2026. As of November 1, 2025, the company has cumulatively repurchased 1,175,000 shares, representing 0.1671% of its total share capital. The repurchases, intended for employee stock ownership plans or equity incentives, involved a total expenditure of CNY 19,996,245, with prices ranging from CNY 16.15 to CNY 17.99 per share. The company aims to repurchase between CNY 30,000,000 and CNY 60,000,000 worth of shares, not exceeding CNY 25 per share.

Concurrently, Wandong Medical and its subsidiaries are actively managing idle funds. The company utilizes CNY 30,000,000 in idle raised funds and CNY 150,000,000 for cash management, while its subsidiary utilizes CNY 60,000,000. These investments predominantly involve bank wealth management products with floating returns, such as the China Merchants Bank Gold Series Callable Two-Tier Range 77-Day Structured Deposit and Bank of Beijing EUR/USD Fixed Daily Observation Range Structured Deposit.

The company has successfully redeemed several matured wealth management products, yielding notable returns. For instance, an CNY 80,000,000 investment in China Merchants Bank's Gold Series 92-day structured deposit matured on June 12, 2025, generating CNY 362,900 in income. As of the latest disclosure, the total approved cash management limit for raised funds is CNY 200,000,000, with CNY 30,000,000 currently utilized. The cash management limit is CNY 800,000,000, with CNY 290,000,000 currently in use.